Recently, Synlight Biosciences, a synthetic biology company, announced the completion of its Series A1 financing round, raising tens of millions of RMB. The round was led by a prominent venture capital firm, with continued participation from several existing investors. The funds will primarily support the acceleration of core product development, expansion of production pipelines, and strengthening of the company’s talent team. Founded in 2021, Synlight Biosciences focuses on leveraging synthetic biology to develop high-value functional bioactive ingredients for applications in food, cosmetics, and the broader health and wellness sector. The company has established an integrated technology platform covering strain engineering, fermentation process optimization, and product application testing, achieving breakthroughs in multiple niche markets. The successful close of this A1 round reflects strong investor confidence in the synthetic biology sector and underscores Synlight’s robust potential in both technological innovation and commercialization. Looking ahead, the company plans to deepen collaborations across the industrial value chain to promote green, sustainable biomanufacturing solutions globally.Synlight Biosciences stated it remains committed to its mission of ‘reimagining biomanufacturing through photosynthetic thinking,’ aiming to empower traditional industries with cutting-edge science and deliver safer, more effective, and eco-friendly bio-based products to consumers.
近日，合成生物学企业心光生物宣布完成数千万元人民币的A1轮融资。本轮融资由知名风险投资机构领投，多家老股东持续跟投，资金将主要用于加速其核心产品的研发、拓展生产管线以及加强团队建设。心光生物成立于2021年，专注于利用合成生物学技术开发高附加值的功能性活性成分，应用于食品、化妆品及大健康领域。公司已构建起从菌株构建、发酵工艺优化到产品应用测试的完整技术平台，并在多个细分赛道实现技术突破。此次A1轮融资的顺利完成，不仅体现了资本市场对合成生物学赛道的高度认可，也彰显了心光生物在技术创新与商业化落地方面的强劲潜力。未来，公司计划进一步深化与产业链上下游的合作，推动绿色、可持续的生物制造解决方案在全球市场的应用。心光生物表示，将持续聚焦‘用光合思维重塑生物制造’的使命，以科技赋能传统产业转型升级，为消费者提供更安全、高效、环保的生物基产品。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/6945.html